PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19776758-0 2010 Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine. Azacitidine 69-82 nucleophosmin 1 Homo sapiens 45-49 35381683-0 2022 (Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report). Azacitidine 134-145 nucleophosmin 1 Homo sapiens 56-60 35063965-9 2022 In patients treated with venetoclax+azacitidine, CRc in patients with FLT3-ITD and FLT3-TKD was 63% and 77%, median OS was 9.9 and 19.2 months, and in co-mutated FLT3-ITD+NPM1, CRc was 70%, median DoR was not reached, and median OS was 9.1 months. Azacitidine 36-47 nucleophosmin 1 Homo sapiens 171-175 25643589-9 2015 Maintenance lenalidomide/azacitidine augmented the function of cytotoxic T lymphocytes, particularly in patients with NPM1 mutation. Azacitidine 25-36 nucleophosmin 1 Homo sapiens 118-122 25643589-10 2015 The lenalidomide/azacitidine maintenance combination was effective in suppressing residual DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A)-positive disease, resulting in sustained remission in patients with concurrent NPM1 mutation. Azacitidine 17-28 nucleophosmin 1 Homo sapiens 223-227 21750085-0 2011 Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Azacitidine 60-71 nucleophosmin 1 Homo sapiens 89-93 22230298-3 2012 Numerous differentially expressed proteins were identified with MALDI-TOF/TOF-MS. Cyclophilin A, Catalase, Nucleophosmin and PCNA were decreased exclusively by azacitidine, TCP1 and hnRNP A2/B1 by both drugs; alpha-Enolase and Peroxiredoxin-1 by decitabine. Azacitidine 160-171 nucleophosmin 1 Homo sapiens 107-120